S.Biomedics Co., Ltd. (KOSDAQ:304360)
20,350
-850 (-4.01%)
At close: Oct 22, 2026
S.Biomedics Revenue
S.Biomedics had revenue of 4.82B KRW in the quarter ending June 30, 2026, with 0.19% growth. This brings the company's total for the last twelve months to 16.49B, down -3.53% year-over-year. In the year 2025, S.Biomedics had annual revenue of 16.55B with 20.49% growth. That makes S.Biomedics the 36,313th largest company in the world by revenue and 2,325th in South Korea.
Revenue (ttm)
16.49B
Revenue Growth
-3.53%
P/S Ratio
15.28
Revenue / Employee
358.53M
Employees
46
Market Cap
252.04B
Revenue by Geography
- South Korea 15.88B 96.0%
- Overseas 664.70M 4.0%
Fiscal year ended Dec 31, 2025 See the full S.Biomedics breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 16.55B | 2.81B | 20.49% |
| Dec 31, 2024 | 13.73B | 625.65M | 4.77% |
| Dec 31, 2023 | 13.11B | 995.73M | 8.22% |
| Dec 31, 2022 | 12.11B | 3.24B | 36.58% |
| Dec 31, 2021 | 8.87B | 3.55B | 66.72% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| HansBiomed | 124.81B |
| ROKIT Healthcare | 32.81B |
| Genome & Company | 24.46B |
| NIBEC | 22.60B |
| curacle co.,ltd. | 8.24B |
| IntoCell | 3.19B |
| Kangstem Biotech | 3.03B |
| Inventage Lab | 2.47B |